Healio

Continuous subcutaneous infusion linked to more ‘on’ time in Parkinson’s

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
Healio

Continuous subcutaneous apomorphine infusion reduces motor fluctuations in PD

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...
Seeking Alpha

U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV ...
Nasdaq

AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

- PRODUODOPA® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's ...
clinicaladvisor.com

Continuous Subcutaneous Insulin Infusion May Reduce Basal Hyperglycemia in T2D

Patients with type 2 diabetes who were initially treated with multiple daily injections were assessed before and after switching to continuous subcutaneous insulin infusion. OPT2MISE was a multicenter ...
Medscape

Prodrugs Infusion Beats Oral PD Therapy for Motor Symptoms

A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...
Nature

Continuous subcutaneous insulin infusion improves glycemic control and quality of life in type 1 diabetes

Hoogma RPLM et al. (2005) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: ...
Medscape

FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
MedPage Today

Continuous Parkinson's Disease Therapy Wins FDA Nod

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
The American Journal of Managed Care

Resource Utilization With Insulin Pump Therapy for Type 2 Diabetes Mellitus

A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use. This study was a ...
Business Insider

Continuous Subcutaneous Insulin Infusion Market Size Worth $7.3 Billion by 2027: Grand View Research, Inc.

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of10.3% over the forecast ...